INTERVIEW

As Election Campaign Begins, LDP’s Eto Says Debate Needed to Possibly Expand 2% Adjustment Rate for Drug Price Revisions

July 4, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Official campaigning kicked off on July 4 for Japan’s July 21 Upper House election, and one candidate with an ear to the industry is Seiichi Eto, 71, an aide to Prime Minister Shinzo Abe who heads up the ruling Liberal Democratic…

To read the full story

LDP’s Eto Secures Upper House Seat
July 22, 2019

INTERVIEW

Interview: Mathematician Changing the Future of Drug Discovery (FRONTEO CTO)
March 25, 2025
From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
“Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…